SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is surging as investors react to the successful Artemis II mission and growing anticipation surrounding potential upcoming lunar contracts. The community is actively discussing the stock's significant momentum, potential for a short squeeze, and its emergence as a key player in the expanding private space infrastructure sector.

Figma, Inc. is an AI-powered design platform that enables seamless collaboration across the entire product development lifecycle. Its products include FigJam, Figma Slides, Figma Design, Figma Draw, Dev Mode, Figma Sites, Figma Buzz and Figma Make. The company was founded by Dylan Joseph Field and Evan Darrow Wallace in 2012 and is headquartered in San Francisco, CA.

Figma Inc. - Ordinary Shares - Class A

Figma

Figma is facing heavy selling pressure amid a broader market rotation out of high-multiple software stocks, with investors weighing concerns over long-term AI disruption against its strong product retention. While many traders see the current weakness as an overreaction and a potential accumulation opportunity, sentiment remains divided as the community debates whether the stock is finding a bottom or heading toward lower valuations.

Maulcoin

Maulcoin is trending as a community-driven project that is actively rallying supporters to increase volume and engagement while waiting for technical issues regarding its ticker and chart integration to be resolved. The community, led by an active developer, positions the token as a transparent, long-term alternative to typical "rug pull" memecoins and is aggressively pushing for higher market capitalization and broader platform visibility.

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class B

Berkshire Hathaway is experiencing high volatility as shareholders react to a significant earnings miss and the company's first quarterly report under CEO Greg Abel. Investors are actively debating the company's massive cash pile, its lack of dividend payments, and whether recent performance signals a strategic decline or an impending opportunity for the new leadership to aggressively deploy capital.

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is trending as a veteran parody project that has evolved from a 2011 BitcoinTalk forum joke into an on-chain meme asset on Solana. The community is actively debating its potential as the original meme coin, drawing comparisons to Bitcoin while leveraging its long-standing lore to attract holders who are positioning for a speculative long-term breakout.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending as investors react to leadership changes in R&D and intensified pressure from activist shareholder Shah Capital, who is demanding strategic overhauls and improved accountability. The community remains deeply divided, with many expressing frustration over persistent price volatility and a lack of clear communication regarding partnership timelines for core vaccine assets.

REalloys, Inc. is engaged in the rebuilding of domestic supply chain resilience for rare earth elements and magnets. It is involved in recycling, mining, oxide production, metallization, alloying, and magnet manufacturing. The company was founded on October 4, 2011 and is headquartered in Boca Raton, FL.

REalloys Inc.

ALOY is trending as investors focus on its role in the U.S. defense supply chain following a recent capital raise and government contracts. Community discussion centers on its long-term potential in rare earth processing versus skepticism regarding its pre-revenue status and recent price volatility.

The centrifuge token model powers centrifuge, providing the framework needed to run the platform without reliance on a single point of failure, including the centrifuge team or Company, and to accelerate its utility. To accomplish this, centrifuge leverages the cryptoeconomic primitives of a native token called the centrifuge token (cfg), a nominated-proof-of-stake consensus algorithm that employs centrifuge to stake value, rewards for centrifuge adoption, and an on-chain governance mechanism that empowers centrifuge holders to guide the development of centrifuge.

Centrifuge

Centrifuge is gaining strong momentum driven by the successful launch of its licensed S&P 500 Index Fund token and recent institutional partnerships. The community remains highly bullish, frequently discussing the project's role in the Real World Asset sector and its potential to bridge traditional finance with decentralized ecosystems.

Nu Holdings Ltd. is a holding company, which engages in the provision of digital banking services. The company was founded by David Vélez Osorno, Cristina Helena Zingaretti Junqueira, and Adam Edward Wible on February 26, 2016 and is headquartered in George Town, Cayman Islands.

Nu Holdings Ltd - Ordinary Shares Class A

Nu Holdings Ltd

Nu Holdings is capturing attention as investors analyze its long-term potential for global expansion, particularly through its pending U.S. national bank charter and aggressive growth in Latin American markets. While the stock has faced recent price volatility and investor frustration over stagnant performance, the community remains divided between those accumulating positions based on strong fundamental growth and those skeptical of the stock's short-term ability to break out of its current range.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is under significant investor scrutiny as shareholders express frustration over stagnant stock performance and conservative long-term guidance despite the company's commercial growth. The community is actively debating the impact of the upcoming TDAPA reimbursement transition, the potential for legislative support via the Kidney Care Access Protection Act, and the clinical prospects of the Rezzayo phase III trial.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Lixte Biotech Holdings (NASDAQ: LIXT) Advances Precision Oncology Strategy with LB-100, Expands Clinical and Strategic Partnerships

Lixte Biotechnology (NASDAQ: LIXT)&#160;is emerging as a differentiated player in the oncology ecosystem, advancing a precision-driven approach to cancer treatment which focuses on improving the effectiveness of existing. As a clinical-stage pharmaceutical company, the company is advancing novel compounds built around a unique biological target, with its lead candidate, LB-100, at the nucleus of its [&#8230;]

LIXTE Biotechnology (NASDAQ: LIXT) Has the World’s Only Clinical-Stage PP2A Inhibitor, Poised to Improve Cancer Treatment Outcomes

LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, is in the unique position of holding the world’s only clinical-stage protein phosphatase 2A (“PP2A”) inhibitor, called LB-100. The LB-100 compound is a proprietary small-molecule PP2A inhibitor that is designed to target protein phosphatase 2A (“PP2A”), introducing a potential new treatment paradigm aimed at enhancing existing&#8230; [&#8230;]

LIXTE Biotechnology (NASDAQ: LIXT) Strengthens Oncology Pipeline Through Expanded LB-100 Clinical Trials

Ovarian clear cell carcinoma and metastatic colon cancer remain among the most challenging malignancies to treat, with limited effective therapies and poor patient outcomes driving the urgent need for new approaches. LIXTE Biotechnology Holdings (NASDAQ: LIXT) is dedicated to addressing that need through the continued development of its lead compound LB-100. Recent updates from the company highlight expanding clinical [&#8230;]

Lixte Biotech (NASDAQ: LIXT) Advances Precision Oncology with LB-100, Strengthens Position Through Liora Technologies Partnership

Lixte Biotech Holdings (NASDAQ: LIXT)&#160;is advancing the frontiers of precision oncology, developing therapies that complement existing cancer treatments while integrating cutting-edge data solutions. The company’s lead program, LB-100, is a novel small-molecule compound designed to enhance the efficacy of chemotherapy and radiation, aiming to improve patient outcomes while reducing treatment-related side effects. By focusing on [&#8230;]

Lixte Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the business of developing a drug class called protein phosphatase 2A inhibitors. The firm is also involved in utilizing biomarker technology to identify enzyme targets associated with serious common diseases and then designing novel compounds to attack those targets. The company was founded by John S. Kovach and Robert B. Royds on May 24, 2005 and is headquartered in Boca Raton, FL.

Current Price	$3.05
Prev Close	$2.90
Open	$2.90
Dividend Yield	0.00%
50-Day Moving Average	$2.99
Beta	0.66
Avg. Volume	39,639.58
PE Ratio	-2.48

52-Week High	$6.26
52-Week Low	$0.64
Market Capitalization	$33.69M
EPS (Annual)	-$1.26
Price to Book	3.38
Revenue Per Employee	$0.00

LIXT
Lixte Biotechnology Holdings Inc

Feed

News

Sentiment

Fundamentals

Info

Latest LIXT News

LIXTLixte Biotechnology Holdings Inc